Showing results (31-40 of 56) with videos related to
Sort By:
Pageof 6
Frontiers in Oncology|January 31, 2020
High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced MelanomaAnn W Silk, Howard L Kaufman, Brendan Curti, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responsesDavid Avigan, Baldev Vasir, Jianlin Gong, et al.Cell Reports. Medicine|February 22, 2023
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinomaJulie Stein Deutsch, Evan J Lipson, Ludmila Danilova, et al.The Lancet. Oncology|March 30, 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialKim Margolin, Marc S Ernstoff, Omid Hamid, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell CarcinomaThomas Denize, Yue Hou, Jean-Christophe Pignon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III TrialsDirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.Cancer Immunology Research|December 23, 2016
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint TherapyXinqi Wu, Anita Giobbie-Hurder, Xiaoyun Liao, et al.Cancer|October 11, 2018
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanomaAhmad A Tarhini, Paul Frankel, Christopher Ruel, et al.BJU International|October 30, 2009
Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart reviewToni K Choueiri, Mei Sheng Duh, Jessica Clement, et al.The New England Journal of Medicine|June 1, 2007
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinomaGary Hudes, Michael Carducci, Piotr Tomczak, et al.Pageof 6